Sign In
1 Apr 2010 09:58
ReNeuron Group PLC ("the Company")
Shareholding
Guildford, UK, 1 April 2010: ReNeuron Group plc (LSE: RENE.L) has received notification that Mr. Charles Good now holds 32,575,000 ordinary shares in the Company, representing 7.442% of the Company's outstanding share capital.
-Ends-
Enquiries:
|
Michael Hunt, Chief Executive Officer Dr John Sinden, Chief Scientific Officer ReNeuron Group plc |
+44 (0) 1483 302560 |
|
|
|
|
Jonathan Birt, Susan Quigley Financial Dynamics |
+44 (0) 20 7831 3113 |
|
|
|
|
Simon Leathers, Emma Earl Daniel Stewart & Company plc |
+44 (0) 20 7776 6550 |
|
|
|
|
Alastair Stratton, Steve Quinn Matrix Corporate Capital LLP |
+44 (0) 20 3206 7000 |
About ReNeuron
ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has regulatory approval for a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. Patient recruitment for this trial is expected to commence shortly. The Company is also developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com
Follow the stocks
